You are here: Industry Insights > boston

News List

Boston Pharmaceuticals signs three-year agreement with GSK pharmaceutical-business-review
March 19, 2021
The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK).
Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area prnasia
January 21, 2021
Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art, cGMP manufacturing site in Europe, announced at the virtual grand opening ceremony ...
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy prnasia
December 21, 2020
Antengene Corporation Limited today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. for oral XPOVIO® (selinexor, ATG-010) ...
Stevanato Group Opens Technology Excellence Center in Boston contractpharma
September 27, 2020
Stevanato Group, a producer of pharmaceutical glass containers and provider of integrated capabilities for drug delivery systems, has officially inaugurated its Technology Excellence Center (TEC) in Boston, Massachusetts.
Xpovio hits endpoints in Phase III multiple myeloma trial pharmatimes
March 06, 2020
Karyopharm has announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor).
Boston Analytical Continues Expansion contractpharma
August 16, 2019
Opens office in Cambridge spurred by double-digit growth.
Boston Biomedical Discontinues Napabucasin Study americanpharmaceuticalreview
July 04, 2019
Boston Biomedical has announced the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with ...
Boston scientific exercises option to acquire Millipede, Inc. biospectrumasia
January 02, 2019
Boston Scientific Corporation has announced that it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif., upon its recent successful completion of a first-in-human clinical study.
KCR Expands U.S. Presence contractpharma
May 11, 2017
Moves to new office in Boston life science hub